4d Pharma PLC Update on Suspension of Trading on AIM (1558B)
RNS Number : 1558B
4d Pharma PLC
29 September 2022
4D pharma plc (in administration)
Delay to publication of Interim Results
Update on Suspension of Trading on AIM
Leeds, UK, September 28, 2022 , - 4D pharma plc (AIM: DDDD), a
pharmaceutical company leading the development of Live
Biotherapeutic products (LBPs), a novel class of drug derived from
the microbiome, announces that it will not report its interim
results for the 6 months to 30 June 2022 by 30 September as
required by Rule 18 of the AIM Rules for Companies (the "AIM
Rules"). This is a consequence of the Company having been placed
into administration on 24 June 2022, when trading in the Company's
ordinary shares were suspended clarification of the Company's
financial position. Accordingly, the suspension will also remain in
place pending announcement of the interim results in accordance
with AIM Rule 18.
Further to the publication of the Joint Administrators'
Proposals on August 4 2022, the Joint Administrators continue to
evaluate potential avenues to return the Company from
administration and this process is ongoing. Further announcements
will be made in due course.
Singer Capital Markets - Nominated Adviser and Joint Broker
Philip Davies / James Fischer (Corporate Finance) +44 (0)20 7496
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D pharma has developed a proprietary platform,
MicroRx(R), that rationally identifies Live Biotherapeutics based
on a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. In addition to those programs listed above,
there are two further clinical stage programs, namely Blautix(R)
which is in development for the treatment of irritable bowel
syndrome (IBS), and which has successfully completed a Phase II
trial, and MRx0518 in patients with solid tumours, which
successfully completed Part A as announced on 9 November 2020.
Additional nonclinical-stage programs of LBPs include therapies for
central nervous system (CNS) diseases, immune-inflammatory
conditions and cancer. 4D pharma has a research collaboration with
MSD (a tradename of Merck & Co., Inc., Kenilworth, NJ, USA), to
discover and develop Live Biotherapeutics for vaccines.
This announcement contains "forward-looking statements." All
statements other than statements of historical fact contained in
this announcement, including without limitation statements
regarding the efficacy of its Live Biotherapeutics including
MRx0006, use of the MicroRx(R) platform to identify candidates, and
the safety and efficacy of Live Biotherapeutics for the treatment
of conditions of the central nervous system (CNS), are
forward-looking statements within the meaning of Section 27A of the
United States Securities Act of 1933, as amended (the "Securities
Act"), and Section 21E of the United States Securities Exchange Act
of 1934, as amended (the "Exchange Act"). Forward-looking
statements are often identified by the words "believe," "expect,"
"anticipate," "plan," "intend," "foresee," "should," "would,"
"could," "may," "estimate," "outlook" and similar expressions,
including the negative thereof. The absence of these words,
however, does not mean that the statements are not forward-looking.
These forward-looking statements are based on the Company's current
expectations, beliefs and assumptions concerning future
developments and business conditions and their potential effect on
the Company. While management believes that these forward-looking
statements are reasonable as and when made, there can be no
assurance that future developments affecting the Company will be
those that it anticipates.
All of the Company's forward-looking statements involve known
and unknown risks and uncertainties, some of which are significant
or beyond its control, and assumptions that could cause actual
results to differ materially from the Company's present
expectations or projections. The foregoing factors and the other
risks that could cause actual results to differ materially include
risks relating to the efficacy of its Live Biotherapeutic drug
candidates including MRx0006, risk related to safety of
investigational therapeutics, pre-clinical and clinical development
risk, and those additional risks and uncertainties described in the
documents filed by the Company with the US Securities and Exchange
Commission ("SEC"). The Company wishes to caution you not to place
undue reliance on any forward-looking statements, which speak only
as of the date hereof. The Company undertakes no obligation to
publicly update or revise any of its forward-looking statements
after the date they are made, whether as a result of new
information, future events or otherwise, except to the extent
required by law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact firstname.lastname@example.org or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
September 29, 2022 05:00 ET (09:00 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Nov 2023 to Dec 2023
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Dec 2022 to Dec 2023